Medicus Pharma Ltd (NASDAQ:MDCX) Short Interest Update

Medicus Pharma Ltd (NASDAQ:MDCX) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 1,105,825 shares, an increase of 24.4% from the January 15th total of 888,655 shares. Based on an average trading volume of 297,800 shares, the days-to-cover ratio is currently 3.7 days. Currently, 4.9% of the shares of the stock are sold short. Currently, 4.9% of the shares of the stock are sold short. Based on an average trading volume of 297,800 shares, the days-to-cover ratio is currently 3.7 days.

Medicus Pharma Stock Performance

MDCX stock traded up $0.07 during trading on Monday, hitting $1.06. 580,222 shares of the company’s stock traded hands, compared to its average volume of 394,977. Medicus Pharma has a 52 week low of $0.92 and a 52 week high of $8.94. The stock has a market capitalization of $27.08 million, a price-to-earnings ratio of -0.49 and a beta of -1.15. The business has a fifty day simple moving average of $1.46 and a 200 day simple moving average of $1.98.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.27). Research analysts forecast that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MDCX has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Medicus Pharma in a report on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and issued a $27.00 target price on shares of Medicus Pharma in a report on Monday, December 15th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Medicus Pharma presently has an average rating of “Hold” and a consensus target price of $23.50.

Hedge Funds Weigh In On Medicus Pharma

Several hedge funds have recently added to or reduced their stakes in MDCX. Jane Street Group LLC bought a new stake in Medicus Pharma in the second quarter worth about $41,000. HRT Financial LP purchased a new stake in shares of Medicus Pharma in the fourth quarter worth approximately $42,000. Osaic Holdings Inc. lifted its stake in shares of Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after acquiring an additional 9,000 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after acquiring an additional 17,611 shares during the period. Finally, Brave Asset Management Inc. bought a new position in Medicus Pharma in the 3rd quarter valued at $46,000.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.